![](https://news.europawire.eu/wp-content/uploads/2013/12/universityofoxford.jpg)
OXFORD, 22-Mar-2017 — /EuropaWire/ — Researchers have started a new gene therapy clinical trial to treat X-linked retinitis pigmentosa (XLRP), the most common cause of blindness in young people. Retinitis pigmentosa is currently untreatable and leads to a slow and irreversible … Read the full press release